ImmuPharma PLC has selected Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes drug, Kapiglucagon. This follows the appointment of Swiss firm Bachem to produce the active ingredient. Kapiglucagon is designed for Type 1 diabetes and aims to support dual-hormone artificial pancreas systems by providing a stable prodrug version of glucagon. The company is preparing for clinical development and plans to submit an investigational new drug application in the US, leveraging a regulatory pathway that uses existing safety data to speed approval.
GE Vernova reported Q2 2026 earnings with an EPS of $2.47, missing the consensus estimate of $3.17, while revenue rose 22% year-over-year to $11.10 billion, beating expectations. Despite strong top-line growth and an upgraded full-year outlook, share...
Packaging Corporation of America is set to release its Q2 2026 earnings on July 22, with analysts expecting revenue of $2.40 billion, a 10.7% increase from last year, driven by higher packaging volume and pricing. However, earnings per share are fore...
The global automotive pumps market is projected to grow from $31.11 billion in 2026 to $34.15 billion by 2035, at a CAGR of 1.0%. Growth is driven by increased pump content in passenger cars, especially for engine and HVAC systems, as OEMs adopt adva...
Celldex Therapeutics lowered its price target from $67 to $61 after stopping its Phase 2 trial for barzolvolimab, a drug for prurigo nodularis, because it failed to meet primary efficacy goals. Despite this setback, the drug showed a strong safety pr...
Equinor reported mixed Q2 2026 results with earnings per share of $1.33, slightly below analyst expectations of $1.38. However, revenue rose to $34.40 billion, surpassing forecasts due to a 3% production increase and higher energy prices. The company...
